Niagen Bioscience (NASDAQ:NAGE) Price Target Lowered to $13.00 at Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE) had its price objective cut by Canaccord Genuity Group from $14.00 to $13.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Niagen Bioscience Stock Up 3.2%

Shares of Niagen Bioscience stock opened at $5.10 on Thursday. The company has a market capitalization of $407.03 million, a PE ratio of 25.50 and a beta of 2.11. Niagen Bioscience has a 52 week low of $4.72 and a 52 week high of $14.69. The stock’s fifty day moving average is $5.77 and its two-hundred day moving average is $7.17.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. increased its holdings in shares of Niagen Bioscience by 28.5% during the fourth quarter. Invesco Ltd. now owns 43,641 shares of the company’s stock valued at $278,000 after acquiring an additional 9,688 shares in the last quarter. Corient Private Wealth LLC purchased a new position in shares of Niagen Bioscience during the fourth quarter worth $204,000. SummitTX Capital L.P. purchased a new stake in Niagen Bioscience in the fourth quarter valued at $79,000. Tudor Investment Corp ET AL acquired a new stake in Niagen Bioscience during the 4th quarter worth about $360,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Niagen Bioscience in the fourth quarter worth about $104,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 blowout results — Niagen reported strong Q4 and FY2025 results with 16% year‑over‑year revenue growth (Q4 net sales $33.8M, Tru Niagen sales $27.5M), improved gross margins (64.1%) and solid profitability metrics that beat estimates; these fundamentals are the main driver of today’s upward move. Niagen Bioscience Reports Q4 & FY2025 Results
• Positive Sentiment: Earnings beat — Niagen beat consensus EPS and revenue estimates for the quarter (EPS topped estimates; revenue and other metrics outperformed), reinforcing investor confidence in near‑term execution. NAGE Tops Q4 Estimates (Zacks)
• Positive Sentiment: After‑hours rally signaled heavy buying interest — the stock spiked in after‑hours trading on the results and commentary, a near‑term technical catalyst that helped push the price up during extended trading. Niagen Bioscience Rallies 18% After Hours (Benzinga)
• Neutral Sentiment: Analyst action: Canaccord lowered its price target slightly from $14 to $13 but kept a Buy rating, leaving a large implied upside — this is not a negative endorsement of the story but tempers near‑term upside expectations. Canaccord Lowers PT to $13 (Benzinga)
• Neutral Sentiment: Investor research/valuation pieces are re‑running after guidance was issued — analysts and value‑modelers are updating forecasts now that management provided FY‑2026 direction, so additional analyst revisions are likely over the next few days. A Look At Niagen Valuation After New 2026 Guidance (Yahoo)
• Negative Sentiment: FY‑2026 revenue guidance came in below consensus — management’s revenue range ($142.4M–$148.8M) is under the Street estimate (~$153.3M), which tempers the upside from the beat and is a potential headwind for the stock if analysts lower forward estimates. Q4 2025 Earnings Call Highlights (Yahoo)

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.